Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Target Raised at Stifel Nicolaus

Vertex Pharmaceuticals (NASDAQ:VRTX) had its target price boosted by analysts at Stifel Nicolaus from $500.00 to $563.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “hold” rating on the pharmaceutical company’s stock. Stifel Nicolaus‘s price objective indicates a potential upside of 1.78% from the company’s previous close.

A number of other analysts also recently issued reports on the stock. Evercore raised their price target on shares of Vertex Pharmaceuticals from $535.00 to $600.00 and gave the stock an “outperform” rating in a report on Wednesday, September 2nd. Barclays upped their price objective on Vertex Pharmaceuticals from $615.00 to $617.00 and gave the company an “overweight” rating in a report on Wednesday, August 5th. Leerink Partners began coverage on Vertex Pharmaceuticals in a research report on Monday, September 21st. They issued an “outperform” rating and a $594.00 price objective for the company. Truist Financial raised their target price on Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, TD Cowen lifted their target price on Vertex Pharmaceuticals from $525.00 to $550.00 and gave the company a “buy” rating in a research report on Wednesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $583.04.

Vertex Pharmaceuticals Stock Down 1.0%

NASDAQ VRTX opened at $553.15 on Tuesday. Vertex Pharmaceuticals has a 52 week low of $403.16 and a 52 week high of $568.67. The business’s fifty day simple moving average is $523.32 and its 200-day simple moving average is $479.96. The firm has a market cap of $140.39 billion, a PE ratio of 32.20, a P/E/G ratio of 2.54 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The firm had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period in the previous year, the firm posted $4.80 EPS. The company’s revenue was up 11.8% compared to the same quarter last year. Research analysts expect that Vertex Pharmaceuticals will post 16.74 EPS for the current year.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. United Advisor Group LLC boosted its stake in shares of Vertex Pharmaceuticals by 17.4% in the third quarter. United Advisor Group LLC now owns 633 shares of the pharmaceutical company’s stock valued at $331,000 after purchasing an additional 94 shares during the period. Plancorp LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth approximately $254,000. May Hill Capital LLC lifted its holdings in Vertex Pharmaceuticals by 4.2% during the 3rd quarter. May Hill Capital LLC now owns 643 shares of the pharmaceutical company’s stock worth $336,000 after buying an additional 26 shares in the last quarter. Ashton Thomas Private Wealth LLC boosted its position in Vertex Pharmaceuticals by 10.4% in the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 2,994 shares of the pharmaceutical company’s stock valued at $1,565,000 after buying an additional 281 shares during the period. Finally, Calamos Wealth Management LLC boosted its position in Vertex Pharmaceuticals by 13.0% in the 3rd quarter. Calamos Wealth Management LLC now owns 1,252 shares of the pharmaceutical company’s stock valued at $655,000 after buying an additional 144 shares during the period. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 11.8% year over year to $3.44 billion, exceeding the $3.42 billion analyst estimate. Growth was supported by continued strength in the cystic fibrosis franchise and increasing contributions from newer products, including CASGEVY and JOURNAVX. Vertex Q3 2026 Earnings Call Transcript
• Positive Sentiment: Vertex raised its full-year 2026 revenue guidance, citing broad-based portfolio growth and the successful completion of its Crinetics Pharmaceuticals acquisition. Management also highlighted its advancing pipeline and a developing nephrology franchise as future growth opportunities. Vertex Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: The transition from Trikafta to newer cystic fibrosis treatment Alyftrek continued to expand the franchise, while the ramp-up of recently launched medicines may diversify Vertex’s long-term revenue base. However, the company is investing heavily in these launches and in the Crinetics deal. Vertex Spends Its CF Growth on New Launches
• Negative Sentiment: Adjusted earnings were $4.76 per share, below analyst expectations of approximately $4.82–$4.92 and down from $4.80 a year earlier. The shortfall reflects increased spending on new product launches, research and development, and the Crinetics acquisition, limiting profit growth despite higher sales. Vertex Misses Q3 Earnings Estimates
• Negative Sentiment: Although full-year revenue guidance was increased, reports characterized the improvement as a light hike that fell short of some investor expectations. That combination—an earnings miss and limited guidance upside—helped pressure the stock despite the revenue beat. Vertex Yo-Yos on Mixed Third-Quarter Report

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.